Phase 3 N=32 Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 29; 5 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=133 Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)
Arthritis, Juvenile Idiopathic
Primary: Number of Subjects in the Non-MTX Stratum With Disease Flare During the Double-Blind Phase — 13; 20 Participants — p=0.031
Phase 4 N=85 Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis
Juvenile Chronic Polyarthritis · Juvenile Idiopathic Arthritis · Juvenile Rheumatoid Arthritis
Primary: Proportion of Participants Who Attain Inactive Disease by 6 Months — 10; 17 participants
Phase 2 N=71 Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults
Juvenile Idiopathic Arthritis
Primary: Time to Response to Treatment, as Determined by a Modified JIA ACR30 Requiring no Fever, Coupled With a Requirement for Corticosteroid Taper in Participants Who Are…
Phase 3 N=193 Pediatric Arthritis Study of Certolizumab Pegol
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Primary: Certolizumab Pegol (CZP) Plasma Concentration Level at Week 16 — 1.6166; 9.2277; 13.8928; 22.9060 ug/ml
Phase 1 N=26 Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)
Juvenile Idiopathic Arthritis
Primary: Apparent Oral Clearance (CL/F) — 28.09; 25.48; 20.53 liter per hour
Phase 3 N=783 Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
Juvenile Idiopathic Arthritis
Primary: Composite of All Primary Endpoints — 13; 14; 41; 245 Participants — p=0.7357
Phase 3 N=112 A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)
Juvenile Idiopathic Arthritis
Primary: Part I: Percentage of Participants With ≥30% Improvement in Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) Core Set and Absence of Fever…
Phase 3 N=225 Efficacy Study Of Tofacitinib In Pediatric JIA Population
Juvenile Idiopathic Arthritis
Primary: Double Blind Phase: Percentage of Participants With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International…
N/A N=100 Sleep Shared-Management Intervention for Children With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Sleep Disturbance — 62.1; 62.4; 57.7; 58.3 T-score
N/A N=113 Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance]
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Treatment-Related Adverse Events of Etanercept — 22 participants
Phase 2 N=6 Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis
Anterior Uveitis · Arthritis, Juvenile Idiopathic · Iritis
Primary: Number of Participants With a Two-step Reduction in Inflammation — 5 participants
Phase 3 N=190 BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
Juvenile Rheumatoid Arthritis
Primary: Time to Occurrence of Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease Flare During Double-Blind Phase (Period B) — NA; 6 months — p=0.0002
Phase 3 N=127 Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
Juvenile Idiopahtic Arthritis
Primary: Number of Participants With Malignancy: All Periods of Parent and Extension Study — 1 Participants
Phase 4 N=12 Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) — 12; 7; 5; 0 participants
Phase 3 N=188 A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Percent of Patients With a Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology 30 (ACR30) Flare in Part II of the Study (Weeks 16-40) — 48.1; 25.6…
Phase 3 N=220 A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Time to Disease Flare — NA; 27.14 Weeks — p=<0.001
Phase 3 N=302 Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Laboratory Test Abnormalities — 294 Participants
Phase 3 N=289 Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Change in Pain Intensity — 3.56; 3.26; 3.07; 2.90 Units on a scale — p=<.001
Phase 3 N=130 A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
Arthritis, Juvenile
Primary: Serum Trough Concentration (C-trough) of Golimumab — 0.50 micrograms per milliliter (mcg/mL)
Phase 3 N=55 An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
Juvenile Psoriatic Arthritis · Enthesitis Related Arthritis
Primary: Percentage of Participants With Juvenile Idiopathic Arthritis American College of Rheumatology (JIA ACR) 30 Response — 100; 100; 100; 100 Percentage of Participants
N/A N=43 Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis
Arthritis
Primary: Positive Serum GMTs at 7 Months (HPV06) — 34 participants
Phase 3 N=7 A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Adverse Events of Special Interest and Study-Drug Related Adverse Events — 6; 0; 1; 1 participants
Phase 4 N=46 A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
Juvenile Idiopathic Arthritis (JIA)
Primary: Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs Leading to Discontinuation (DC) of Study Drug — 4…
N/A N=16 Sleep Innovations for Preschoolers With Arthritis (SIPA): Developing and Pilot Testing of a Self-Management Intervention
Juvenile Idiopathic Arthritis
Primary: Feasibility as Assessed by Adherence — 12 Participants
N/A N=375 Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis
Arthritis, Juvenile Rheumatoid
Primary: Change From Baseline in DAS28-4/ESR at Week 4 — -1.01 units on a scale — p=< 0.0001
Phase 3 N=86 Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)
Juvenile Psoriatic Arthritis · Enthesitis-related Arthritis
Primary: Number of Participants Experiencing a Flare During Treatment Period 2 — 10; 21 Participants — p=<0.001
Phase 2 N=102 An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)
Juvenile Idiopathic Arthritis
Primary: Maximum Serum Concentration (Cmax) of Sarilumab at Week 12 — 7.57; 13.7; 22.0; 33.6 milligram per liter (mg/L)
Phase 3 N=69 Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)
Juvenile Rheumatoid Arthritis
Primary: Percentage of Participants With Disease Flare in Part 2 — 81; 28 percentage of participants — p=0.0030
Phase 3 N=20 Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan
Juvenile Idiopathic Arthritis
Primary: Percentage of Participants Experiencing a American College of Rheumatology (ACR) Pediatric 30 Response at Week 16 — 90.0 percentage of participants